Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Athenex, a US-China Biopharma, Files for $100 Million US IPO

publication date: May 19, 2017
Athenex, a US-China biopharma, filed to raise $100 million in a US IPO on the NASDAQ exchange. Athenex has developed a platform that develops oral formulations of existing chemotherapies. Its lead product is an oral form of paclitaxel (Oraxol), which it is developing along with oral irinotecan, docetaxel and topotecan. In 2016, Athenex raised $200 million from New York State -- the company is headquartered in Buffalo, New York -- in return for a promise to provide manufacturing jobs.  One year earlier, Athenex struck a similar deal with Chongqing, China to build two manufacturing facilities there. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital